Neurocrine Biosciences and Voyager Therapeutics announce positive phase 1 results of genetic therapy for Parkinsons disease.

Results Confirm the Posterior Trajectory as an Additional Surgical Delivery Route for VY-AADC in Patients with Parkinson’s DiseaseTreatment with VY-AADC Improved Good ON Time (ON Time Without Troublesome Dyskinesia) by 1.7 Hours and Reduced OFF Time by 2.2 Hours at 12 Months in Patients with Parkinson’s Disease SAN DIEGO, CA and CAMBRIDGE, MA, USA I May 05, 2019 I ...